BEST UNLIMITED TURBO LONG CERTIFICATE - NOVO-NORDISK B | Market Closed - Euronext Paris 12:30:00 2024-06-28 EDT | ||
| 32.34 EUR | -0.11% |
|
| Current month | +15.93% | ||
| 1 month | +16.06% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 32.39 | +0.03% |
| 24-06-27 | 32.38 | -0.65% |
| 24-06-26 | 32.59 | -2.47% |
| 24-06-25 | 33.42 | +6.14% |
| 24-06-24 | 31.48 | -0.42% |
Real-time Euronext Paris
Last update June 28, 2024 at 12:30 pm
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| SN26S | |
| ISIN | DE000SQ3UKM5 |
| Date issued | 2022-11-04 |
| Strike | 404.6 kr |
| Maturity | Unlimited |
| Parity | 2.5 : 1 |
| Emission price | 3.12 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 34.33 € |
|---|---|
| Lowest since issue | 1.857 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006
DKK
Average target price
949.7
DKK
Spread / Average Target
-5.56%
- Stock Market
- Certificates
- SN26S Certificat
